SCHEMBL3882866

SCHEMBL3882866

O=C(c1cccc(CNS(=O)(=O)c2ccc(-c3ccccc3)cc2)c1)N1CCOCC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.62
▸ PKM P14618 1/20 0.62
▸ HSD11B1 P28845 1/20 0.58
▸ ALDH1A1 P00352 6/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ LMNA P02545 3/20 0.57
▸ GAA P10253 2/20 0.57
▸ HPGD P15428 4/20 0.56
▸ HTT P42858 3/20 0.56
▸ CASP1 P29466 1/20 0.56
▸ CASP7 P55210 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ NPC1 O15118 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ TSHR P16473 1/20 0.50
▸ RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3873492 0.90 RAB9A (0.76) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3887286 0.90 RAB9A (0.60) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3873960 0.89 PKM (0.74) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3874296 0.89 SMN1; SMN2 (0.62) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3874054 0.88 RAB9A (0.62) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3873285 0.87 ALDH1A1 (0.54) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3873710 0.87 PKM (0.61) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3873358 0.86 CYP19A1 (0.61) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3877687 0.82 ALDH1A1 (0.54) RAB9APKMHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL3873636 0.81 CYP19A1 (0.59) GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 — — EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 — — US disclosed
EP-1814846-A1 11BETA-HSD1 INHIBITORS Evotec AG (DE) 2007-08-08 — — EP disclosed
WO-2006048330-A1 11ΒΕΤΑ-HSD1 INHIBITORS EVOTEC AG (DE) 2006-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 RAB9A 4300/4885PKM 1568/4885HSD11B1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback